For Emergency Use, US FDA May Visit Rather Than Inspect COVID-19 Vaccine Manufacturing Sites

Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
authorized visits could be in store for covid vaccine sites

If a COVID-19 vaccine were authorized for emergency use, it would occur without pre-license inspections of the manufacturing facilities, a US FDA official acknowledged at a 22 October meeting of the agency’s Vaccines and Related Biological Products Advisory Committee.

The agency might instead simply visit the facilities.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet